Price History

Hover for the daily close. The dotted line marks the period open.

Compare SCYX with… →

SCYX Key Statistics

As of Sep 4, 2026

Trading

Open: $5.31
Previous Close: $5.35
Day's Range: 5.18–5.45
52-Week Range: 3.53–10.48
Volume: 55.50K
Beta: 1.11

Valuation

Market Cap: $52.73M
P/E Ratio: unprofitable
P/S ratio: 2.74
EPS (ttm): −0.91

Financials (FY)

Revenue (FY): $20.60M+449.95%
Net Income (FY): −$8.61M
Profit margin: −53.26%
Shares Outstanding: 9.95M
1-Year Return: −23.76%

Dividend and dates

Earnings Date: November 4, 2026estimated
Avg Volume: 138.09K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SCYX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−79.22%+88.80%+4.83%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+4.83%
2025	−47.77%
2024	−45.74%
2023	+42.95%
2022	−74.43%
2021	−20.26%
2020	−15.93%
2019	+88.80%
2018	−79.22%
2017	−27.27%
2016 (partial year)	+52.63%

As of September 4, 2026.

SCYX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$20.60M	−$8.61M	−41.8%
2024	$3.75M	−$21.29M	−568.3%
2023	$140.14M	$67.04M	47.8%
2022	$5.09M	−$62.81M	−1233.7%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$20.60M	—	−$16.07M	−$8.61M	−41.8%
2024	$3.75M	$3.75M	−$37.12M	−$21.29M	−568.3%
2023	$140.14M	$124.52M	$72.67M	$67.04M	47.8%
2022	$5.09M	$4.46M	−$85.76M	−$62.81M	−1233.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SCYX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks

Metric	SCYX	Drug Manufacturers - Specialty & Generic median	vs median
P/S ratio	2.74	2.30	20% above
Profit margin	−53.26%	−3.14%	50.1 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

SCYNEXIS, Inc. (SCYX) is capitalised at $52.73M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 18 employees.

The most recent close on file for SCYX is $5.30, dated September 4, 2026. That is −$0.04 (−0.84%) against the previous close. Over the past 52 weeks the price has ranged from $3.53 to $10.48. The latest close sits 50.14% above that 52-week low.

Financial Health

In fiscal 2025, SCYNEXIS, Inc. reported revenue of $20.60M. Against the prior fiscal year total of $3.75M, that is a change of +449.95%. The same year closed with a net loss of $8.61M. The reported profit margin is −53.26%. That is 50.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.91.

Across the 4 fiscal years on file, revenue moves from $5.09M in 2022 to $20.60M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.74. On price-to-sales that is 19.51% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −23.76%. Across 10 years the annualized return works out at −31.13%. The reported beta is 1.11. Annualized volatility over the trailing 10 years is 80.27%.

Growth & Income

The record shows no dividend for SCYX.

So far in 2026 the price is +4.83%. The strongest complete calendar year on file is 2019 at +88.80%; the weakest is 2018 at −79.22%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

SCYNEXIS, Inc. (SCYX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
SCYNEXIS, Inc.	SCYX	$52.73M	—
Takeda Pharmaceutical Company Limited	TAK	$58.92B	—
Teva Pharmaceutical Industries Limited	TEVA	$42.37B	60.6
Haleon plc	HLN	$42.22B	20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. SCYNEXIS, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

TEVA

Teva Pharmaceutical Industries Limited

$42.37B

HLN

Haleon plc

$42.22B

ZTS

Zoetis Inc.

$31.33B

UTHR

United Therapeutics Corporation

$20.91B

VTRS

Viatris Inc.

$19.39B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Visit website →

SCYNEXIS, Inc. (SCYX) Stock Analysis